
Opinion|Videos|June 3, 2024
Alzheimer’s Disease Pipeline
Key opinion leaders discuss the Alzheimer's disease pipeline and the numerous disease-modifying therapies under investigation.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Please provide an overview of robust Alzheimer’s pipeline and many disease modifying therapies under investigation.
- Discuss novel and emerging treatments that are most advanced in clinical studies or have promising data:
- Valiltramiprosate (ALZ-801,inhibits amyloid oligomer formation, oral)
- ALN-APP (RNAi therapeutic)
- Blarcamesine (sigma-1 and muscarinic receptors ligand)
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 Biomarker Data Shows Valiltramiprosate Reduces Plasma p-Tau217 in APOE4/4 Carriers
2
AAIC 2026 Preview: David Wolk, MD, on Biomarkers, Disease Heterogeneity, and What's Next in Alzheimer Research
3
Rethinking Clinical Trial Design and the Immune System in Multiple Sclerosis: Ahmed Obeidat, MD, PhD
4
Looking Beyond Gene Therapy for Treating Charcot-Marie-Tooth Disease: Carla Taveggia, PhD
5



















